"Liberty777, your posts are well thought out and reasonable. With respect to the $300k revenue/year - that genuinely is trailing 12 months, not forward looking. No guarantees of course, but the next 12 months could certainly show improvement. The past 12 months were a difficult period for many companies. The massive dilution is also a matter of opinion. What if that Dilution enabled the Company to build multiple valuable long term opportunities, such as Pharmaceutical Development. One could argue that the Company could have had less dilution but also much less opportunity to build value. It's really not black and white. Everything is a balancing act, but it's possible that Tauriga's management got it right and the dilution was in the best interest of shareholders" and whatever dilution that there was or wasn't - Also enabled Tauriga to hold onto its entire VTGN position. Which - is effectively like Reducing dilution Because that share appreciation is organic appreciation of balance sheet.